Example 600 ABSTRACT

26th EAHPCONGRESS23-25MARCH

Vielan 2022 hospital pharmacists changing roles in a changing world

EAHP thanks the continued support of its Partners



#EAHP2022

EVALUATION OF THE COST OF MANAGING ADVERSE EVENTS

RELATED TO CYTOTOXIC DRUGS IN CHILDREN

S. MOUSANNIF¹, A. MEFTAH², H. ATTJIOUI³, S. MOUID³, A. ABOUTALIB³, Z. ABDERRAHIM³, D. TALHIK³, A. CHEIKH⁴, M. BOUATIA¹. ¹MOHAMMED V UNIVERSITY-FACULTY OF MEDICINE AND PHARMACY- PAEDIATRIC HOSPITAL, PHARMACY DEPARTMENT, RABAT, MOROCCO. ²PEDIATRIC HOSPITAL RABAT, PHARMACY DEPARTMENT, RABAT, MOROCCO. ³MOHAMMED V UNIVERSITY-FACULTY OF MEDICINE AND PHARMACY OF RABAT, PHARMACY DEPARTMENT, RABAT, MOROCCO. ⁴CHEIKH ZAID HOSPITAL, PHARMACY DEPARTMENT, RABAT, MOROCCO.

*mousannif.soumaya@gmail.com

NUMBER : 4CPS-075 / ATC code: 2. Case studies - with patient consent

Background and importance

Aim and objectives

Despite the public health importance of the problems posed by

cancer, there are few studies focusing on the economic aspects,

particularly those devoted to second-line treatment, to manage

the secondary events associated with cytotoxic drugs.

The objective of this study is to estimate and evaluate the cost of the

management of secondary events following chemotherapy

treatments at pediatric hemato-oncology department in pediatric

hospital of rabat.

Material and methods

This is an "indirect cost of illness" study conducted from the analysis of 63 medical records of children with 8 different types of cancer who

all received cisplatin in their chemotherapy protocols. And who are treated in the pediatric hemato-oncology department of Rabat.

Results

We analyzed 45 files out of 63 because of the unavailability of the files at the time of the analysis.

□ 80% of the patients were still under treatment, 7% under palliative treatment, 13% died.

Neuroblastoma represents 51%, Malignant Germ Cell Tumor 13%, Medulloblastoma 11%, Osteosarcoma 9%, Nasopharyngeal

Undifferentiated Carcinoma 7%, Hepatoblastoma 5% and 2% each for Metastatic Rhabdomyosarcoma and Sacrococcygeal Teratoma.

Only sacrococcygeal teratoma and metastatic rhabdomyosarcoma which showed 127 management in front of the appeared side effects,

88% of the drugs were administered, 5.5% the cures were shifted, 4.7% the cures were stopped and in 1.8% the dosages were reduced.

Based on the cost of the drugs administered for the treatment of these two types of cancer, we note a total of 4500 euros in addition to

the cost of chemotherapy.

To compensate the side effects caused by chemotherapy : 46.5% of patients were transfused with red blood cells, 11% of patients by

platelets cells, 22% of patients received ceftriaxone as antibiotic therapy, paracetamol was administered in 11% of cases.

Conclusion

According to the results found, the cost of management of secondary events related to cytotoxic drugs is considerable, so it is necessary to

focus on other studies to evaluate the pharmacoeconomic impact of the indirect costs of diseases

Keywords

Cost / Manage / Adverse events / Cytotoxic drugs / Children